{"id":22554,"date":"2023-01-19T23:42:00","date_gmt":"2023-01-19T15:42:00","guid":{"rendered":"https:\/\/flcube.com\/?p=22554"},"modified":"2025-01-21T23:51:25","modified_gmt":"2025-01-21T15:51:25","slug":"nhsa-updates-2022-national-reimbursement-drug-list-with-2967-drug-varieties","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=22554","title":{"rendered":"NHSA Updates 2022 National Reimbursement Drug List with 2,967 Drug Varieties"},"content":{"rendered":"\n<p>The National Healthcare Security Administration (NHSA) has revealed the results of the 2022 National Reimbursement Drug List (NRDL) update. The finalized NRDL now includes a total of 2,967 drug varieties, comprising 1,586 western medicines, 1,381 Chinese patent drugs, and 892 traditional Chinese medicines in ready-to-use forms. Among western drugs, there were 83 new entrants and 80 renewals for existing listings.<\/p>\n\n\n\n<p><strong>Competitive Bidding for Non-Exclusive Products<\/strong><br>For the first time, the update adopted competitive bidding for non-exclusive products. A total of 17 non-exclusive drugs entered the list via this method, with the lowest priced bid setting the reimbursement benchmark price. Products may be marketed above this price, but patients are required to pay any excess over the reimbursement benchmark.<\/p>\n\n\n\n<p><strong>Implementation and Pricing<\/strong><br>All provincial, autonomous region, and municipal drug centralized procurement bodies are required to adopt the new drug list and make products available for online procurement by the end of February 2023. For manufacturers of non-exclusive products that participated in the competitive bidding, online procurement prices must not exceed their quoted bid prices.<\/p>\n\n\n\n<p><strong>Negotiations and Success Rates<\/strong><br>A total of 147 drugs participated in on-site negotiations and competitive bidding, with 121 winners and an overall success rate of 82.3%. The 108 new entrants (including traditional Chinese medicines) were required to make an average price cut of 60.1%, similar to last year&#8217;s NRDL update. The new listings cover 23 disease groups, including 56 chronic disease drugs (hypertension, diabetes, mental illness), 23 oncology drugs, 17 anti-infection drugs, and 7 rare disease drugs. Among these are 22 pediatric formulations, 2 COVID-19 drugs, and 2 national essential drugs. A total of 24 domestically developed innovative drugs entered negotiations, with 20 successes.<\/p>\n\n\n\n<p><strong>Renewals and Manufacturer Highlights<\/strong><br>Two drugs renewed existing NRDL listings for a third time, the first occurrence of this: Novartis\u2019s Afinitor (everolimus) and Kanghong Pharma\u2019s Lumitin (conbercept). Novartis topped the rankings with 1 new entrant and 13 renewals, while Jiangsu Hengrui Medicine had the largest number of new entrants at 5, alongside 3 renewals.<a href=\"https:\/\/flcube.com\/\"><\/a><a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Manufacturer<\/th><th>New Entrants<\/th><th>Renewals<\/th><th>Total<\/th><\/tr><\/thead><tbody><tr><td>Novartis<\/td><td>1<\/td><td>13<\/td><td>14<\/td><\/tr><tr><td>Hengrui Medicine<\/td><td>5<\/td><td>3<\/td><td>8<\/td><\/tr><tr><td>AstraZeneca<\/td><td>0<\/td><td>6<\/td><td>6<\/td><\/tr><tr><td>Pfizer<\/td><td>4<\/td><td>2<\/td><td>6<\/td><\/tr><tr><td>Takeda<\/td><td>3<\/td><td>2<\/td><td>5<\/td><\/tr><tr><td>Roche<\/td><td>3<\/td><td>1<\/td><td>4<\/td><\/tr><tr><td>MSD<\/td><td>3<\/td><td>1<\/td><td>4<\/td><\/tr><tr><td>Hansoh Pharma<\/td><td>1<\/td><td>3<\/td><td>4<\/td><\/tr><tr><td>BeiGene<\/td><td>1<\/td><td>2<\/td><td>3<\/td><\/tr><tr><td>J&amp;J<\/td><td>1<\/td><td>2<\/td><td>3<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><a href=\"https:\/\/flcube.com\/\"><\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The National Healthcare Security Administration (NHSA) has revealed the results of the 2022 National Reimbursement&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[4],"tags":[101,67],"class_list":["post-22554","post","type-post","status-publish","format-standard","hentry","category-policy-regulatory","tag-nationally-negotiated-drugs","tag-nhsa-prev-smia"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>NHSA Updates 2022 National Reimbursement Drug List with 2,967 Drug Varieties - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"The National Healthcare Security Administration (NHSA) has revealed the results of the 2022 National Reimbursement Drug List (NRDL) update. The finalized NRDL now includes a total of 2,967 drug varieties, comprising 1,586 western medicines, 1,381 Chinese patent drugs, and 892 traditional Chinese medicines in ready-to-use forms. Among western drugs, there were 83 new entrants and 80 renewals for existing listings.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=22554\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NHSA Updates 2022 National Reimbursement Drug List with 2,967 Drug Varieties\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=22554\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-19T15:42:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-21T15:51:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22554#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22554\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"NHSA Updates 2022 National Reimbursement Drug List with 2,967 Drug Varieties\",\"datePublished\":\"2023-01-19T15:42:00+00:00\",\"dateModified\":\"2025-01-21T15:51:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22554\"},\"wordCount\":338,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Nationally negotiated drugs\",\"NHSA (prev. SMIA)\"],\"articleSection\":[\"Policy \\\/ Regulatory\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=22554#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22554\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=22554\",\"name\":\"NHSA Updates 2022 National Reimbursement Drug List with 2,967 Drug Varieties - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-01-19T15:42:00+00:00\",\"dateModified\":\"2025-01-21T15:51:25+00:00\",\"description\":\"The National Healthcare Security Administration (NHSA) has revealed the results of the 2022 National Reimbursement Drug List (NRDL) update. The finalized NRDL now includes a total of 2,967 drug varieties, comprising 1,586 western medicines, 1,381 Chinese patent drugs, and 892 traditional Chinese medicines in ready-to-use forms. Among western drugs, there were 83 new entrants and 80 renewals for existing listings.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22554#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=22554\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22554#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NHSA Updates 2022 National Reimbursement Drug List with 2,967 Drug Varieties\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"NHSA Updates 2022 National Reimbursement Drug List with 2,967 Drug Varieties - Insight, China&#039;s Pharmaceutical Industry","description":"The National Healthcare Security Administration (NHSA) has revealed the results of the 2022 National Reimbursement Drug List (NRDL) update. The finalized NRDL now includes a total of 2,967 drug varieties, comprising 1,586 western medicines, 1,381 Chinese patent drugs, and 892 traditional Chinese medicines in ready-to-use forms. Among western drugs, there were 83 new entrants and 80 renewals for existing listings.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=22554","og_locale":"en_US","og_type":"article","og_title":"NHSA Updates 2022 National Reimbursement Drug List with 2,967 Drug Varieties","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=22554","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-01-19T15:42:00+00:00","article_modified_time":"2025-01-21T15:51:25+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=22554#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=22554"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"NHSA Updates 2022 National Reimbursement Drug List with 2,967 Drug Varieties","datePublished":"2023-01-19T15:42:00+00:00","dateModified":"2025-01-21T15:51:25+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=22554"},"wordCount":338,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Nationally negotiated drugs","NHSA (prev. SMIA)"],"articleSection":["Policy \/ Regulatory"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=22554#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=22554","url":"https:\/\/flcube.com\/?p=22554","name":"NHSA Updates 2022 National Reimbursement Drug List with 2,967 Drug Varieties - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-01-19T15:42:00+00:00","dateModified":"2025-01-21T15:51:25+00:00","description":"The National Healthcare Security Administration (NHSA) has revealed the results of the 2022 National Reimbursement Drug List (NRDL) update. The finalized NRDL now includes a total of 2,967 drug varieties, comprising 1,586 western medicines, 1,381 Chinese patent drugs, and 892 traditional Chinese medicines in ready-to-use forms. Among western drugs, there were 83 new entrants and 80 renewals for existing listings.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=22554#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=22554"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=22554#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"NHSA Updates 2022 National Reimbursement Drug List with 2,967 Drug Varieties"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/22554","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=22554"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/22554\/revisions"}],"predecessor-version":[{"id":22555,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/22554\/revisions\/22555"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=22554"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=22554"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=22554"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}